The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial

Joseph J. Eron(University of North Carolina at Chapel Hill), Mark S. Shaefer(Research Triangle Park Foundation), Christine Katlama(Université Paris Cité), Philip Lackey, Cindy Vavro(Research Triangle Park Foundation), Denise Sutherland‐Phillips(Research Triangle Park Foundation), Paul Wannamaker(Research Triangle Park Foundation), Schlomo Staszewski(National Institute of Allergy and Infectious Diseases), Benjamin Young(Cornell University), Jane Yeo(GlaxoSmithKline (United Kingdom)), Edwin DeJesus(Orlando Immunology Center), Patrick Yéni, Joseph Gathe, Lisa Patel(Research Triangle Park Foundation), Linda Yau(Research Triangle Park Foundation), Vicente Estrada(Instituto de Salud Carlos III)
The Lancet
August 1, 2006
10.1016/s0140-6736(06)69155-1
Cited by 343

Related Papers

Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy
|JAMA|2016|1.4k
Decline in the AIDS and death rates in the EuroSIDA study: an observational study
|The Lancet|2003|1.2k
Treatment for Adult HIV Infection
|JAMA|2006|1k
Antiretroviral Therapy in Adults
|JAMA|2000|1k
Antiretroviral Treatment of Adult HIV Infection
|JAMA|2008|1k